GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
06 May 2014 03:28 PM
RNS
Director/PDMR Shareholding
02 May 2014 05:38 PM
RNS
Director/PDMR Shareholding
02 May 2014 05:38 PM
RNS
Director/PDMR Shareholding
02 May 2014 05:34 PM
RNS
Director/PDMR Shareholding
02 May 2014 05:34 PM
RNS
Director/PDMR Shareholding
02 May 2014 05:31 PM
RNS
Director/PDMR Shareholding
01 May 2014 12:24 PM
RNS
Total Voting Rights
01 May 2014 07:00 AM
RNS
GSK receives US approval for Incruse Ellipta
30 Apr 2014 12:00 PM
RNS
1st Quarter Results
28 Apr 2014 04:11 PM
RNS
GSK Receives EU Marketing Authorisation - Incruse
28 Apr 2014 03:36 PM
RNS
Director/PDMR Shareholding
22 Apr 2014 07:01 AM
RNS
GSK announces major transaction with Novartis
17 Apr 2014 04:58 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:58 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:56 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:56 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:52 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:50 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:50 PM
RNS
Director/PDMR Shareholding
17 Apr 2014 04:24 PM
RNS
GSK receives approval in Canada for Incruse
15 Apr 2014 05:56 PM
RNS
Tanzeum (albiglutide) receives FDA approval
15 Apr 2014 03:39 PM
RNS
Director/PDMR Shareholding
15 Apr 2014 03:36 PM
RNS
Director/PDMR Shareholding
14 Apr 2014 04:34 PM
RNS
Director/PDMR Shareholding
11 Apr 2014 03:17 PM
RNS
Director/PDMR Shareholding
11 Apr 2014 03:15 PM
RNS
Director/PDMR Shareholding
11 Apr 2014 11:03 AM
RNS
Director/PDMR Shareholding
10 Apr 2014 03:14 PM
RNS
Director/PDMR Shareholding
10 Apr 2014 03:12 PM
RNS
Director/PDMR Shareholding
08 Apr 2014 04:11 PM
RNS
Director/PDMR Shareholding
08 Apr 2014 04:10 PM
RNS
Director/PDMR Shareholding
02 Apr 2014 10:52 AM
RNS
Director/PDMR Shareholding
02 Apr 2014 07:00 AM
RNS
Update on Phase lll clinical trial of MAGE-A3
01 Apr 2014 12:52 PM
RNS
Total Voting Rights
31 Mar 2014 03:16 PM
RNS
Director/PDMR Shareholding
31 Mar 2014 07:00 AM
RNS
GSK data from PIII STABILITY study of darapladib
26 Mar 2014 01:07 PM
RNS
Eperzan (albiglutide) receives EMA approval
26 Mar 2014 10:17 AM
RNS
Notice of AGM
26 Mar 2014 10:07 AM
RNS
Regulatory update on combined use of MEK/BRAF
24 Mar 2014 09:56 AM
RNS
Director/PDMR Shareholding
21 Mar 2014 11:32 AM
RNS
GSK - historical restated financial information
20 Mar 2014 07:00 AM
RNS
MAGE-A3 MAGRIT Phase III trial results
17 Mar 2014 03:59 PM
RNS
Director/PDMR Shareholding
17 Mar 2014 03:56 PM
RNS
Director/PDMR Shareholding
13 Mar 2014 04:00 PM
RNS
Additional Listing
12 Mar 2014 05:08 PM
RNS
Mepolizumab Positive Phase III Asthma Study Result
12 Mar 2014 04:34 PM
RNS
Director/PDMR Shareholding
12 Mar 2014 04:23 PM
RNS
Director/PDMR Shareholding
10 Mar 2014 07:00 AM
RNS
GSK increases stake in its Indian pharma. co.
06 Mar 2014 10:57 AM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings